Breast Cancer Awareness Month, held each year in October with the 21st dedicated to National Mammography Day 2022 designed to to improve support and screening for the disease.

In this article, we will take a closer look at all of the new guidelines, therapies and innovations that have been introduced since Breast Cancer Awareness Month 2021.

Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

FREE DIGITAL POCKET GUIDE

American Society of Clinical Oncology (ASCO)
Published May 2022

Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

FREE DIGITAL POCKET GUIDE

American Society of Clinical Oncology (ASCO)
Published May 2022

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer

FREE DIGITAL POCKET GUIDE

American Society of Clinical Oncology (ASCO)
Published November 2021

Other Breast Cancer-Related Clinical Practice Guidelines

Breast Cancer-Related Medications

  • Verzenio (Eli Lilly) In combination with endocrine therapy (tamoxifen or an aromatase inhibitor), for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at high risk of recurrence and a Ki-67 score of ≥20% as determined by an FDA-approved test. Ki-67 is a marker of cellular proliferation.
  • Lynparza (AstraZeneca) Adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.
  • Enhertu (Daiichi Sankyo/AstraZeneca) Treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.
  • Enhertu (Daiichi Sankyo/AstraZeneca) Treatment of patients with unresectable or metastatic HER2-low breast cancer.

Looking Ahead

As we look ahead towards Breast Cancer Awareness Month 2023, we can almost certainly expect new and updated clinical guidelines for Breast Cancer from American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN). Especially as ASCO has joined NCCN in transitioning to a living guidelines model, with frequent rapid and focused updates occurring as needed, rather than one major update every few years.

Also on the horizon between now and Breast Cancer Awareness Month 2023 are pending FDA approvals from Radius Pharma (Elacestrant), Gilead (Trodelvy) and potentially a few others.

Copyright © 2022 Guideline Central, All rights reserved.